Activity Date: 04/24/2018
This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.
1:30-1:32 PM: Session and Speaker Introduction
Austin Campbell, PharmD, BCPP
1:32-1:46 PM: Psychotropics and Priapism: A Painful, Personal Problem
Bradley Burk, PharmD
Priapism refers to an inadvertent, painful, and prolonged erection, and is considered to be a urologic emergency. Psychotropic medications have been implicated as being the most common causes of medication-induced priapism. This clinical pearl will describe a particular case with psychotropic-induced priapism from different psychotropic medications in a patient with treatment-resistant schizoaffective disorder. Case reports, and a published article from the Journal of Clinical Psychopharmacology, testing the primary hypothesis of psychotropic-induced priapism, are presented. The clinician will be educated on the relative safety of antipsychotics with respect to priapism induction, in aims of preventing this clinical dilemma. Treatment modalities for priapism will also be covered.
1:46-2:00 PM: Antipsychotic Drug Selection with Cobicistat-Containing Antiretroviral Regimens
Farah Khorassani, PharmD, BCPP, BCPS
The prevalence of HIV in patients with serious mental illness (SMI) is greater than in patients who are not infected with HIV. Regimen selection is individualized based on factors including potential adverse effects, pill burden, resistance test results, and drug-drug interaction potential. Elvitegravir/cobicistat/tenofovir/emtricitabine is one of the preferred regimens recommended as initial therapy for most patients with HIV per the 2017 Panel on Antiretroviral Guidelines for Adults and Adolescents. This is a commonly prescribed regimen in psychiatric population given the low pill burden and ease of administration. Cobicistat, a pharmacokinetic (PK) enhancer and component of this regimen, is a strong cytochrome P450 (CYP) 3A4 inhibitor, and significantly increases the concentration of several CYP 3A4 metabolized antipsychotics. Through evaluation of a case, this clinical pearl will orient pharmacists to the potential drug-drug interactions between cobicistat and CYP 3A4 metabolized antipsychotics and provide guidance on proper agent selection and dosage adjustment.
2:00-2:14 PM: Treatment of Catatonia in Adolescent Patients
Kristin Waters, PharmD, BCPS
Although catatonia has been described as early as the 1870s, most current evidence focuses on its treatment in adult patients. Catatonia, characterized by a distinct set of psychomotor disturbances, can have significant adverse outcomes including malnutrition, deep vein thrombosis or pulmonary embolism, pressure ulcers, and an increased risk of neuroleptic malignant syndrome. The treatment of children and adolescents presenting with catatonic symptoms is therefore imperative despite the paucity of evidence derived from clinical controlled trials. The goal of this presentation is to review five cases of catatonia in adolescent patients (ages 15 to 19 years) treated on an inpatient adolescent psychiatric unit within approximately one year. Treatment strategies, including electroconvulsive therapy and benzodiazepines, will be discussed along with clinical outcomes.
2:14-2:28 PM: Catatonia Following Organ Transplant: Beyond Benzodiazepines or ECT
Suzanne Harris, PharmD, BCPP
2:28-2:30 PM: Session Conclusion
Austin Campbell, PharmD, BCPP
To receive ACPE credit for the live session at the Annual Meeting, you must:
This course will be provided at the CPNP 2018 Annual Meeting, April 22-25, 2018. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Bradley Burk, PharmD
Suzanne Harris, PharmD, BCPP
Farah E. Khorassani, PharmD, BCPS, BCPP
Kristin Waters, PharmD, BCPS
Psychotropics and Priapism: A Painful, Personal Problem
Antipsychotic Drug Selection with Cobicistat-Containing Antiretroviral Regimens
Treatment of Catatonia in Adolescent Patients
Catatonia Following Organ Transplant: Beyond Benzodiazepines or ECT
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hour of knowledge-based continuing education credit from CPNP approved programming.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2018 CPNP Program Committee Disclosures
Elayne D. Ansara, PharmD, BCPP, BCPS |
Jennifer Bean, PharmD, BCPP, BCPS |
|
Jolene R. Bostwick, PharmD, BCPS, BCPP Associate Chair & Clinical Associate Professor, Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor, MI No Relevant Financial Relationships to Disclose |
|
Sheila R. Botts, PharmD, BCPP, FCCP Chief of Clinical Pharmacy Research and Academic Affairs Kaiser Permanente-Colorado Aurora, CO Educational Grants, Research Grants or Contracts: Kaiser Permanente Center for Safety and Effectiveness Non-Financial Interests: Board of Pharmacetical Specialties Psychiatric Pharmacy Specialty Council |
Bridget Bradley, PharmD, BCPP |
Austin R. Campbell, PharmD, BCPP |
|
Andria F. Church, PharmD, BCPS Assistant Professor Larkin University College of Pharmacy Miami, FL No Relevant Financial Relationships to Disclose |
Kelly N. Gable, PharmD, BCPP |
|
Kristen N. Gardner, PharmD Clinical Pharmacy Specialist - Behavioral Health Kaiser Permanente Colorado Denver, CO Employment: Kaiser Permanente Colorado |
Cindy A. Gutierrez, PharmD, BCPP, MS |
Robert J. Haight, PharmD, BCPP |
|
Michael Kotlyar, PharmD, MS Associate Professor University of Minnesota Minneapolis, MN No Relevant Financial Relationships to Disclose |
|
Megan Maroney, PharmD, BCPP Clinical Associate Professor Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey Long Branch, NJ External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Pharmacy Times, Jannsen Pharmacueticals - Advisory board, Otsuka Pharmaceuticals - Speakers Bureau |
Leigh Anne Nelson, PharmD, BCPP |
|
Rosana C. Oliveira, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Psychiatry South Texas Veterans Health Care System San Antonio, TX No Relevant Financial Relationships to Disclose |
Gerald P. Overman, PharmD, BCPP |
Emma C. Palmer, PharmD, BCPS, BCPP |
|
Lindsey Peters, PharmD, BCPS Assistant Professor of Pharmacy Practice Ohio Northern University Ada, OH No Relevant Financial Relationships to Disclose |
|
Melody Ryan, PharmD, BCPS, BCGP, FCCP Professor University of Kentucky Lexington, KY No Relevant Financial Relationships to Disclose |
|
Kristyn Straw, PharmD, BCPP Mental Health Pharmacist Southern Arizona VA Health Care System Tucson, AZ No Relevant Financial Relationships to Disclose |
Daina Wells, PharmD, BCPP, BCPS |
|
Gabriela D. Williams, PharmD, BCPS, BCPP Clinical Pharmacy Specialist, Psychiatry Eskenazi Health Indianapolis, IN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: Kristin Waters: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Lorazepam and other benzodiazepines, zolpidem, amobarbital Suzanne Harris: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Will be primarily discussing off-labeled use of benzodiazepines, zolpidem, and memantine in catatonia. Other off-labeled medications for catatonia such as antipsychotics, amantadine, and bromocriptine will be mentioned in one comparison slide of all treatments
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
